Biohaven's spinal muscular atrophy drug fails to meet study goal
By Mariam Sunny (Reuters) -Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to ...
Is your child not crawling? They could have THIS rare disease
Early diagnosis of rare diseases like Spinal Muscular Atrophy (SMA) is crucial for managing symptoms and improving quality of ...
Taiwan News5 天
Spinal Muscular Atrophy Market Size, Latest Trends, Share, Growth Analysis, and Forecast 2032
FDA Approval of Zolgensma, first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), has become a milestone in the treatment of patients with SMA. It ...
The American Journal of Managed Care6 天
Decoding SMA Progression: HFMSE Analysis Spotlights Variability
The authors emphasize the value of subgroup analyses for tracking patterns in spinal muscular atrophy (SMA), as opposed to ...
biopharma-reporter7 天
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial
Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
FierceBiotech8 天
Biohaven fails phase 3 SMA test but plans talks with FDA, plots move into obesity
A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech ...
BioPharma Dive8 天
Biohaven muscle drug misses goal of SMA study, but advances in obesity
The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the ...
Fun run in support of spinal muscular atrophy patients
OVER 2,000 people participated in a charity fun run themed “Together We Care” aimed at raising awareness and support for individuals affected by spinal muscular atrophy (SMA).